全文获取类型
收费全文 | 28524篇 |
免费 | 1410篇 |
国内免费 | 97篇 |
专业分类
耳鼻咽喉 | 679篇 |
儿科学 | 1193篇 |
妇产科学 | 401篇 |
基础医学 | 3080篇 |
口腔科学 | 572篇 |
临床医学 | 1766篇 |
内科学 | 7639篇 |
皮肤病学 | 1116篇 |
神经病学 | 1992篇 |
特种医学 | 756篇 |
外科学 | 4472篇 |
综合类 | 118篇 |
一般理论 | 6篇 |
预防医学 | 2255篇 |
眼科学 | 756篇 |
药学 | 1638篇 |
中国医学 | 71篇 |
肿瘤学 | 1521篇 |
出版年
2023年 | 142篇 |
2022年 | 85篇 |
2021年 | 633篇 |
2020年 | 269篇 |
2019年 | 691篇 |
2018年 | 1087篇 |
2017年 | 648篇 |
2016年 | 568篇 |
2015年 | 637篇 |
2014年 | 660篇 |
2013年 | 1066篇 |
2012年 | 1858篇 |
2011年 | 2027篇 |
2010年 | 1097篇 |
2009年 | 815篇 |
2008年 | 1682篇 |
2007年 | 1868篇 |
2006年 | 1740篇 |
2005年 | 1752篇 |
2004年 | 1569篇 |
2003年 | 1507篇 |
2002年 | 1493篇 |
2001年 | 1089篇 |
2000年 | 1358篇 |
1999年 | 1002篇 |
1998年 | 156篇 |
1997年 | 100篇 |
1996年 | 113篇 |
1995年 | 74篇 |
1994年 | 53篇 |
1993年 | 52篇 |
1992年 | 345篇 |
1991年 | 250篇 |
1990年 | 204篇 |
1989年 | 155篇 |
1988年 | 157篇 |
1987年 | 158篇 |
1986年 | 121篇 |
1985年 | 111篇 |
1984年 | 84篇 |
1983年 | 63篇 |
1981年 | 34篇 |
1979年 | 57篇 |
1976年 | 33篇 |
1974年 | 31篇 |
1973年 | 37篇 |
1972年 | 29篇 |
1971年 | 28篇 |
1970年 | 25篇 |
1968年 | 28篇 |
排序方式: 共有10000条查询结果,搜索用时 56 毫秒
1.
2.
3.
4.
Jose M. Morales Jose Angel Martinez-Flores Manuel Serrano Maria José Castro Francisco Javier Alfaro Florencio García Miguel Angel Martínez Amado Andrés Esther González Manuel Praga Estela Paz-Artal Antonio Serrano 《Journal of the American Society of Nephrology : JASN》2015,26(3):735-745
In the current immunosuppressive therapy era, vessel thrombosis is the most common cause of early graft loss after renal transplantation. The prevalence of IgA anti–β2-glycoprotein I antibodies (IgA-aB2GPI-ab) in patients on dialysis is elevated (>30%), and these antibodies correlate with mortality and cardiovascular morbidity. To evaluate the effect of IgA-aB2GPI-ab in patients with transplants, we followed all patients transplanted from 2000 to 2002 in the Hospital 12 de Octubre prospectively for 10 years. Presence of IgA-aB2GPI-ab in pretransplant serum was examined retrospectively. Of 269 patients, 89 patients were positive for IgA-aB2GPI-ab (33%; group 1), and the remaining patients were negative (67%; group 2). Graft loss at 6 months post-transplant was significantly higher in group 1 (10 of 89 versus 3 of 180 patients in group 2; P=0.002). The most frequent cause of graft loss was thrombosis of the vessels, which was observed only in group 1 (8 of 10 versus 0 of 3 patients in group 2; P=0.04). Multivariate analysis showed that the presence of IgA-aB2GPI-ab was an independent risk factor for early graft loss (P=0.04) and delayed graft function (P=0.04). There were no significant differences regarding patient survival between the two groups. Graft survival was similar in both groups after 6 months. In conclusion, patients with pretransplant IgA-aB2GPI-ab have a high risk of early graft loss caused by thrombosis and a high risk of delayed graft function. Therefore, pretransplant IgA-aB2GPI-ab may have a detrimental effect on early clinical outcomes after renal transplantation. 相似文献
5.
6.
7.
8.
9.
Ana M. Gómez Angelica Imitola Diana Henao Maira García-Jaramillo Marga Giménez Clara Viñals Bruno Grassi Mariana Torres Isabella Zuluaga Oscar Mauricio Muñoz Martin Rondón Fabián León-Vargas Ignacio Conget 《Diabetes & Metabolic Syndrome: Clinical Research & Reviews》2021,15(1):267-272
Background and aimsDespite using sensor-augmented pump therapy (SAPT) with predictive low-glucose management (PLGM), hypoglycemia is still an issue in patients with type 1 Diabetes (T1D). Our aim was to determine factors associated with clinically significant hypoglycemia (<54 mg/dl) in persons with T1D treated with PLGM-SAPT.Methodology: This is a multicentric prospective real-life study performed in Colombia, Chile and Spain. Patients with T1D treated with PLGM-SAPT, using sensor ≥70% of time, were included. Data regarding pump and sensor use patterns and carbohydrate intake from 28 consecutive days were collected. A bivariate and multivariate Poisson regression analysis was carried out, to evaluate the association between the number of events of <54 mg/dl with the clinical variables and patterns of sensor and pump use.Results188 subjects were included (41 ± 13.8 years-old, 23 ± 12 years disease duration, A1c 7.2% ± 0.9). The median of events <54 mg/dl was four events/patient/month (IQR 1–10), 77% of these events occurred during day time. Multivariate analysis showed that the number of events of hypoglycemia were higher in patients with previous severe hypoglycemia (IRR1.38; 95% CI 1.19–1.61; p < 0.001), high glycemic variability defined as Coefficient of Variation (CV%) > 36% (IRR 2.09; 95%CI 1.79–2.45; p < 0.001) and hypoglycemia unawareness. A protector effect was identified for adequate sensor calibration (IRR 0.77; 95%CI 0.66–0.90; p:0.001), and the use of bolus wizard >60% (IRR 0.74; 95%CI 0.58–0.95; p:0.017).ConclusionIn spite of using advanced SAPT, clinically significant hypoglycemia is still a non-negligible risk. Only the identification and intervention of modifiable factors could help to prevent and reduce hypoglycemia in clinical practice. 相似文献